WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > USV PRIVATE LIMITED
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Medical
Ratio Therapeutics | June 13, 2022
Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial scientists Jack Hoppin, Ph.D., and John Babich, Ph.D., Ratio emerges from stealth mode with more than $20 million in seed funding, fully funded development alliances with Bayer AG and Lantheus Holdings Inc., a robust portfolio of assets developed with two proprietary technologies, and a growing team of world-class expert...
Lilly | June 01, 2020
Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in just three months after AbCellera and the Vaccine Research Center at t...
MedTech, Industrial Impact
Ribbon Biolabs | December 21, 2022
Ribbon Biolabs, the DNA synthesis company announced the successful implementation of their innovative InfiniSynthTM platform for the automated assembly of sequence-agnostic and long DNA. Ribbon Biolabs achieved this milestone in collaboration with HighRes® Biosolutions, a leading laboratory automation technology company. The InfiniSynthTM platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach to providing critical tools for life science research and...
Industry Outlook
Globenewswire | May 29, 2023
Monte Rosa Therapeutics, Inc. a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases. “MRT-6160 is a potent, orally bioavai...
Medical, Industry Outlook
Whitepaper
MedTech
Video
Research, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE